| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
,25-Dihydroxyvitamin D31
University of Colorado Health Sciences Center, Department of Pathology, Denver, Colorado 80262
The LNCaP prostatic carcinoma cell line was examined for the presence of specific receptors for 1
,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. Whole cell binding studies identified approximately 2500 high-affinity (Kd = 1.4 x 10–9) binding sites per cell. Competition studies revealed that these receptors are specific for the 1,25(OH)2 metabolite. Binding studies using the synthetic androgen R1881 indicate that separate androgen and vitamin D3 receptors exist in LNCaP cells. The vitamin D3 receptors sediment at approximately 3.5S on linear sucrose gradients. The sedimentation coefficient could be shifted with a monoclonal anti-vitamin D3 receptor antibody (9A7
) but not with a monoclonal antibody to the androgen receptor (AN1-15). The receptor/ligand complex elutes from native DNA cellulose at 0.2 M KCl. Northern blot analysis identified an mRNA of approximately 4.6 kilobases which hydridized with a specific vitamin D3 receptor complementary DNA probe (hVDR). In the absence of androgens, 1,25(OH)2D3 stimulated growth and prostate-specific antigen production by LNCaP cells in a dose-dependent fashion. Dose-response curves indicated that at physiological concentrations (10–9 M) 1,25(OH)2D3 was mitogenic, whereas at higher concentrations (10–8 M) it promotes differentiation. These studies suggest that 1,25(OH)2D3 could play an important role in the natural history of and response to hormone therapy by prostatic cancer.
1 This work was supported in part by a grant from the Cancer League of Colorado (G. J. M.).
2 To whom requests for reprints should be addressed, at Department of Pathology (B216), University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262.
Received 9/10/91. Accepted 11/14/91.
This article has been cited by other articles:
|
|
 |
|
  S. Attia, J. Eickhoff, G. Wilding, D. McNeel, J. Blank, H. Ahuja, A. Jumonville, M. Eastman, D. Shevrin, M. Glode, et al. Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2437 - 2443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu, F. Fang, D. K. St. Clair, S. Josson, P. Sompol, I. Spasojevic, and W. H. St. Clair Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1{alpha},25-dihydroxyvitamin D3 in prostate cancer cells Mol. Cancer Ther., July 1, 2007; 6(7): 2048 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Fakih, D. L. Trump, J. R. Muindi, J. D. Black, R. J. Bernardi, P. J. Creaven, J. Schwartz, M. G. Brattain, A. Hutson, R. French, et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors Clin. Cancer Res., February 15, 2007; 13(4): 1216 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Cicek, X. Liu, F. R. Schumacher, G. Casey, and J. S. Witte Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2549 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Beer, M. Garzotto, B. Park, M. Mori, A. Myrthue, N. Janeba, D. Sauer, and K. Eilers Effect of Calcitriol on Prostate-Specific Antigen In vitro and in Humans. Clin. Cancer Res., May 1, 2006; 12(9): 2812 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giovannucci, Y. Liu, M. J. Stampfer, and W. C. Willett A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 203 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. John, G. G. Schwartz, J. Koo, D. Van Den Berg, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer Cancer Res., June 15, 2005; 65(12): 5470 - 5479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P Dwivedi, P. H Anderson, J. L Omdahl, H L. Grimes, H. A Morris, and B. K May Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells Endocr. Relat. Cancer, June 1, 2005; 12(2): 351 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Young, G. G. Schwartz, L. Wang, D. P. Jamieson, L. W. Whitlatch, J. N. Flanagan, B. L. Lokeshwar, M. F. Holick, and T. C. Chen The prostate 25-hydroxyvitamin D-1{alpha}-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D Carcinogenesis, June 1, 2004; 25(6): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. Stewart and N. L. Weigel Vitamin D and Prostate Cancer Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Yang and K. L. Burnstein Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm J. Biol. Chem., November 21, 2003; 278(47): 46862 - 46868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crescioli, P. Ferruzzi, A. Caporali, R. Mancina, A. Comerci, M. Muratori, M. Scaltriti, G. B. Vannelli, S. Smiroldo, R. Mariani, et al. Inhibition of Spontaneous and Androgen-Induced Prostate Growth by a Nonhypercalcemic Calcitriol Analog Endocrinology, July 1, 2003; 144(7): 3046 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Peehl, A. V. Krishnan, and D. Feldman Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer J. Nutr., July 1, 2003; 133(7): 2461S - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Polek, L. V. Stewart, E. J. Ryu, M. B. Cohen, E. A. Allegretto, and N. L. Weigel p53 Is Required for 1,25-Dihydroxyvitamin D3-Induced G0 Arrest But Is Not Required for G1 Accumulation or Apoptosis of LNCaP Prostate Cancer Cells Endocrinology, January 1, 2003; 144(1): 50 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rao, R. D. Woodruff, W. N. Wade, T. E. Kute, and S. D. Cramer Genistein and Vitamin D Synergistically Inhibit Human Prostatic Epithelial Cell Growth J. Nutr., October 1, 2002; 132(10): 3191 - 3194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Liu, K. Oettel, G. Ripple, M. J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, R. Marnocha, R. Bruskewitz, R. Mazess, et al. Phase I Trial of 1{alpha}-Hydroxyvitamin D2 in Patients with Hormone Refractory Prostate Cancer Clin. Cancer Res., September 1, 2002; 8(9): 2820 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Holt, N. Arber, B. Halmos, K. Forde, H. Kissileff, K. A. McGlynn, S. F. Moss, K. Fan, K. Yang, and M. Lipkin Colonic Epithelial Cell Proliferation Decreases with Increasing Levels of Serum 25-Hydroxy Vitamin D Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 113 - 119. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Martin and S. L. Pattison Insulin-Like Growth Factor Binding Protein-3 Is Regulated by Dihydrotestosterone and Stimulates Deoxyribonucleic Acid Synthesis and Cell Proliferation in LNCaP Prostate Carcinoma Cells Endocrinology, July 1, 2000; 141(7): 2401 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Zhao, D. M. Peehl, N. M. Navone, and D. Feldman 1{alpha},25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms Endocrinology, July 1, 2000; 141(7): 2548 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Barreto, G. G. Schwartz, R. Woodruff, and S. D. Cramer 25-Hydroxyvitamin D3, the Prohormone of 1,25-Dihydroxyvitamin D3, Inhibits the Proliferation of Primary Prostatic Epithelial Cells Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 265 - 270. [Abstract] [Full Text]
|
|
|
|
|
|
T. C. Chen, G. G. Schwartz, K. L. Burnstein, B. L. Lokeshwar, and M. F. Holick The in Vitro Evaluation of 25-Hydroxyvitamin D3 and 19-nor-1{{alpha}},25-Dihydroxyvitamin D2 as Therapeutic Agents for Prostate Cancer Clin. Cancer Res., March 1, 2000; 6(3): 901 - 908. [Abstract] [Full Text]
|
|
|
|
|
|
T. Habuchi, T. Suzuki, R. Sasaki, L. Wang, K. Sato, S. Satoh, T. Akao, N. Tsuchiya, N. Shimoda, Y. Wada, et al. Association of Vitamin D Receptor Gene Polymorphism with Prostate Cancer and Benign Prostatic Hyperplasia in a Japanese Population Cancer Res., January 1, 2000; 60(2): 305 - 308. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Smith, C. S. Johnson, C. C. Freeman, J. Muindi, J. W. Wilson, and D. L. Trump A Phase I Trial of Calcitriol (1,25-Dihydroxycholecalciferol) in Patients with Advanced Malignancy Clin. Cancer Res., June 1, 1999; 5(6): 1339 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Lokeshwar, G. G. Schwartz, M. G. Selzer, K. L. Burnstein, S.-H. Zhuang, N. L. Block, and L. Binderup Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089 Cancer Epidemiol. Biomarkers Prev., March 1, 1999; 8(3): 241 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Zhao, L. H. Ly, D. M. Peehl, and D. Feldman Induction of Androgen Receptor by 1{alpha},25-Dihydroxyvitamin D3 and 9-cis Retinoic Acid in LNCaP Human Prostate Cancer Cells Endocrinology, March 1, 1999; 140(3): 1205 - 1212. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Xue, M. Lipkin, H. Newmark, and J. Wang Influence of Dietary Calcium and Vitamin D on Diet-Induced Epithelial Cell Hyperproliferation in Mice J Natl Cancer Inst, January 20, 1999; 91(2): 176 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Zhuang and K. L. Burnstein Antiproliferative Effect of 1{alpha},25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation Endocrinology, March 1, 1998; 139(3): 1197 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Zhao, L. H. Ly, D. M. Peehl, and D. Feldman 1{alpha},25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent Endocrinology, August 1, 1997; 138(8): 3290 - 3298. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
